Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

"Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development fo

r the Treatment of Hereditary Angioedema

Company Plans to Use Private Placement Financing Proceeds of $110 Million to Complete IND-Enabling Studies, Pha

se 1a and Phase 1b/2 Clinical Trials of QLS-215..."

020121 Catabasis Pharmaceuticals Announc
Download • 243KB

Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887



MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC